Observational studyJapanese journal of radiology2026
Carbon-Ion radiotherapy alone for inoperable locally advanced Non-Small cell lung cancer: A Japanese National registry study (J-CROS-LUNG).
Observational study in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Definitive radiotherapy for non-small-cell lung cancer: current practice and future directions.Japanese journal of radiology · 2026Review
- Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeCarbon-ion radiotherapy (CIRT) offers high-dose concentration and enhanced biological effects. Since 2016, a nationwide prospective registry study of CIRT for locally advanced non-small cell lung cancer (LA-NSCLC) has been conducted in Japan. This study aimed to evaluate clinical outcomes of CIRT in patients with LA-NSCLC who were ineligible for surgery or chemoradiotherapy (CCRT). MATERIALS AND
methodsPatients with inoperable LA-NSCLC treated with CIRT in Japan from May 2016 to June 2020 were included. Most patients received 64-72 Gy in 16 fractions per the Japanese Society for Radiation Oncology (JASTRO) unified policy. Elective nodal irradiation was allowed for nodal disease. No systemic therapy was administered before or after CIRT. Overall and progression-free survival were estimated by the Kaplan-Meier method; local failure was evaluated using the cumulative incidence function (CIF) with Gray's test. Two-sided P < 0.05 was considered significant.
resultsMedian follow-up was 28 months for all patients and 36 months for survivors. Of the 55 patients, clinical stages (UICC 8th) were: IIB (26), IIIA (17), and IIIB (12). A clinical diagnosis without histological confirmation was established in four patients (7.3%), and interstitial pneumonia (IP) was present in nine (16.4%). The 3-year overall survival and progression-free survival were 49.1% (95% confidence interval [CI], 33.8-62.7%) and 28.3% (95% CI, 16.6-41.3%), respectively. Using competing risks, the 3-year CIF was 37.4% (95% CI, 24.2-50.5%). No grade ≥ 4 toxicity was observed; grade 2 and 3 pneumonitis occurred in 3 (5.5%) and 2 (3.6%) patients, respectively. In multivariable analysis, concomitant IP was a significant factor for overall survival (P = 0.011).
conclusionCIRT demonstrated favorable tumor control with acceptable toxicity in patients with LA-NSCLC ineligible for surgery or CCRT. It may be a promising treatment option for this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.